Impact Biomedical Inc.
Impact BioMedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships.
Business. IMPACT BIOMEDICAL INC. (NYSE: IBO) is a healthcare company operating within the pharmaceuticals industry. The firm generates revenue through the sale of pharmaceutical products. Specific details regarding operating segments and geographic presence are not available. The company is primarily listed on the New York Stock Exchange.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
IMPACT BIOMEDICAL INC. (NYSE: IBO) is a healthcare company operating within the pharmaceuticals industry. The firm generates revenue through the sale of pharmaceutical products. Specific details regarding operating segments and geographic presence are not available. The company is primarily listed on the New York Stock Exchange.
Impact BioMedical Inc. has a highly leveraged capital structure with a current ratio of 0.22, indicating that its current liabilities significantly exceed its current assets. The company's liquidity position is further strained by a negative operating cash flow of -$464,000 and a cash and equivalents balance of only $20,000. Despite having no debt, the company's equity base is modest at $11.46 million, and its market cap of $67.6 million suggests a high valuation multiple relative to its revenue of $7 million.
The company's profitability metrics are deeply negative, with a return on equity of -19.95% and a return on assets of -13.39%. These figures are far below the industry norms for pharmaceutical companies, which typically exhibit positive returns on equity and assets. The company's operating income of -$2.29 million and net income of -$2.29 million for Q1 2026 underscore its ongoing financial challenges.
Impact BioMedical Inc. generates revenue primarily through its biopharmaceutical and wellness offerings, but the company does not disclose specific segment or geographic revenue breakdowns in its filings. The lack of detailed segment reporting makes it difficult to assess the company's exposure to different markets or product lines. However, the company's focus on licensing and co-development partnerships suggests a diversified approach to revenue generation.
The company's growth trajectory is uncertain, with no clear indication of revenue growth in the near term. The company's operating income and net income have remained negative, and there is no evidence of a turnaround in the current fiscal year. The company's future performance will depend on its ability to secure new partnerships and advance its pipeline of healthcare and wellness offerings.
The company faces several risk factors, including liquidity constraints and the potential for dilution. The risk assessment indicates a high liquidity risk due to the company's negative operating cash flow and low cash reserves. Additionally, the company has a medium dilution risk, as it has issued additional shares in the past and may do so in the future to fund operations. The company's financial statements also mention commitments and contingencies, which could impact its financial stability.
Recent filings and financial statements indicate that the company has been working to backfill key financial metrics such as accounts receivable and property and equipment. The company's balance sheet shows a decline in total assets from $17.4 million at the end of 2025 to $17.09 million in Q1 2026, while total liabilities have increased from $1.85 million to $2.38 million. These trends suggest ongoing financial pressures and the need for the company to secure additional funding or generate revenue to sustain operations.
- Impact BioMedical Inc. has a highly leveraged capital structure with a current ratio of 0.22, indicating significant liquidity constraints.
- The company's profitability metrics are deeply negative, with a return on equity of -19.95% and a return on assets of -13.39%.
- The company's revenue is primarily generated through biopharmaceutical and wellness offerings, but it lacks detailed segment or geographic revenue breakdowns.
- The company's growth trajectory is uncertain, with no clear indication of revenue growth in the near term.
- The company faces high liquidity risk and medium dilution risk, with potential for further share issuance to fund operations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue $7.0k; Operating income -$2.3M.
- ▍Revenue $7.0k
- ▍Operating income -$2.3M
- ▍Net margin -32671.4%
Revenue $25.0k; Operating income -$3.1M.
- ▍Revenue $25.0k
- ▍Operating income -$3.1M
- ▍Net margin -68332.0%
Revenue $7.0k; Operating income -$2.2M.
- ▍Revenue $7.0k
- ▍Operating income -$2.2M
- ▍Net margin -223057.1%
Revenue $32.0k; Operating income -$4.3M.
- ▍Revenue $32.0k
- ▍Operating income -$4.3M
- ▍Net margin -36993.8%
Operating income -$28.8M.
- ▍Operating income -$28.8M
Operating income -$28.8M.
- ▍Operating income -$28.8M
Operating income -$4.0M.
- ▍Operating income -$4.0M
Operating income -$4.0M.
- ▍Operating income -$4.0M
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Current liabilities exceed current assets.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- IMPACT BIOMEDICAL INC. company facts · 2026-05-28
- IMPACT BIOMEDICAL INC. 10-Q 2026-05-12 · 2026-05-28
- IMPACT BIOMEDICAL INC. 10-K 2026-03-11 · 2026-05-28
- IMPACT BIOMEDICAL INC. 10-Q 2025-11-07 · 2026-05-28
- IMPACT BIOMEDICAL INC. 10-Q 2025-08-14 · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Frank D. HeuszelChairman of the Board, Chief Executive Officer
Insider activity
- Chief Financial Officer · Common StockSold 43 400 @ $0,56$24K · 2026-03-27
- Chief Financial Officer · Common StockSold 1 600 @ $0,60$961 · 2026-03-25
- Director · Common StockSold 50 000 @ $0,65$33K · 2026-03-23
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on equity (FY 2025-12-31): -96.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.35xDerived (calculated)
- Return on assets (FY 2025-12-31): -68.0%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.15xDerived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -85.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 189.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 33.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 83.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -14.2%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 85.1%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 52.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -99.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 83.5%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2022-12-31): -36.0%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 22.3%Derived (calculated)
- Net margin (FY 2025-12-31): -36,993.8%Derived (calculated)
- Net income (annual): USD -11.84MSEC XBRL filing
- Shareholders' equity (annual): USD 12.31MSEC XBRL filing
- Total assets (annual): USD 17.41MSEC XBRL filing
- Shares outstanding (annual): 104.62MSEC XBRL filing
- Operating cash flow (annual): USD -1.89MSEC XBRL filing
- Current liabilities (annual): USD 1.16MSEC XBRL filing
- Current assets (annual): USD 411KSEC XBRL filing
- Operating income (annual): USD -4.28MSEC XBRL filing